Astrotech (DE) (ASTC) vs EyePoint (EYPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Astrotech (DE) (ASTC) has outperformed EyePoint (EYPT) over the past year, gaining 28.2% versus a loss of 98.3%. Over five years, ASTC leads with a -85.6% price change compared with -98.6% for EYPT. EyePoint is the larger company by market cap ($26.6 million vs $7.4 million), about 3.6 times the size, while Astrotech (DE) is growing revenue faster (-8.7% vs -27.5%).
EyePoint converts more of its revenue into profit, with a net margin of -739.4% versus -1580.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASTC | EYPT |
|---|---|---|
| Share price | $3.50 | $0.2342 |
| Market cap | $7.45M | $26.65M |
| 1-day change | -0.85% | -11.36% |
| YTD return | +1.16% | -98.72% |
| 1-year return | +28.21% | -98.29% |
| 5-year return | -85.60% | -98.58% |
| EPS (TTM) | $-7.88 | $-3.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $913.00K | $31.37M |
| Revenue growth (YoY) | -8.70% | -27.50% |
| Net income (latest FY) | $-14.43M | $-231.96M |
| Gross margin | 23.77% | — |
| Operating margin | -1548.52% | -775.98% |
| Net margin | -1580.18% | -739.42% |
| 52-week high | $68.85 | $19.11 |
| 52-week low | $1.92 | $0.2277 |
| Distance from 52-week high | -94.92% | -98.77% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +10963.19% |
| Average volume | 30.46K | 8.37M |
| Shares outstanding | 2.13M | 113.78M |
| Employees | — | 214 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EyePoint is about 3.6 times larger than Astrotech (DE) by market value ($26.65M vs $7.45M).
- ASTC has outperformed EYPT by 126.5 percentage points over the past year.
- EyePoint is more profitable, keeping -739.4 cents of every revenue dollar as net income versus -1580.2 cents for Astrotech (DE).
- Astrotech (DE) grew revenue faster in its latest fiscal year (-8.70% vs -27.50%).
About Astrotech (DE)
ASTC stock →Astrotech Corporation operates as a mass spectrometry company worldwide. It owns and licenses the intellectual property related to the Astrotech Mass Spectrometer Technology, a platform mass spectrometry technology.
Industrials · Biotechnology: Laboratory Analytical Instruments
About EyePoint
EYPT stock →EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees
ASTC vs EYPT FAQ
Which is bigger, Astrotech (DE) or EyePoint?
EyePoint (EYPT) is larger, with a market capitalization of $26.65M compared with $7.45M for Astrotech (DE) (ASTC).
Which stock has performed better over the past year, ASTC or EYPT?
ASTC returned +28.21% over the past 12 months, compared with -98.29% for EYPT (price return, excluding dividends). Past performance does not predict future results.
Are Astrotech (DE) and EyePoint in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.